Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: wvalx who wrote (21877)	5/11/1999 5:22:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

wvalx, Let me tell you what I understand thus far on the premature ejaculation product: It will be delivered transurethrally. It is a drug that has already been proven to be safe and effective. The patent's strength is more on the side of the delivery method and not the drug. There is not going to be a need for a phase I clinical trial since the drug being used already has a proven safety profile. I guess you can call the trials Vivus will do later this year a phaseI/II clinical trial. This is why we never heard anything about a phase I clinical trial ie because it never happened and is not required by the FDA. If things go smoothly I see no reason why Vivus can't get this product onto the market as early as the end of 2001. I think 3 to 5 years is the worse case scenario. On another note, I think our focus now should be on international launches of MUSE, progression of Alibra and what exactly Vivus is doing to progress the female SD product. I understand that they had a list of about 50 names picked but they were all already trademarked so even coming up with a good name that is not taken has become a challenge.